STSA — Satsuma Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
U.S. STOCKS ON THE MOVE-Immunic, Novavax, PayPal
U.S. STOCKS ON THE MOVE-Satsuma, defense stocks, Top Ships
SVB Securities upgrades Satsuma Pharma ahead of late-stage migraine drug data
Satsuma Pharma extends gains on positive data for migraine therapy study
Satsuma Pharma at 2-yr high as migraine product shows positive tolerability
Brief: Satsuma Pharmaceuticals Announces Positive Results From The Ongoing STS101 Ascend Phase 3 Open-Label, Long-Term Safety Trial
Satsuma Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Satsuma Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Satsuma Pharmaceuticals Reports Fourth Quarter Loss Per Share Of $0.49
Brief: Satsuma Abstracts Accepted For Presentation At American Academy Of Neurology 2022 Annual Meeting
Satsuma Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results And Provides Corporate Update
Brief: Satsuma Pharmaceuticals Posts Q2 Loss Per Share Of $0.38
Satsuma Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Satsuma Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Royal Caribbean, Etsy, L Brands
U.S. STOCKS ON THE MOVE-Royal Caribbean, Carnival, United Airlines, Tupperware
U.S. STOCKS ON THE MOVE-Core Laboratories, BIT Mining, Skillsoft
Mizuho confident on Satsuma Pharma's migraine product STS101; upgrades